Numerous studies have indicated that markedly increased levels of LGALS3BP in serum or tumor tissues have been linked to adverse clinical outcomes in various malignancies, such as neuroblastoma, glioblastoma, breast cancer, and endometrial cancer [28–32]. This evidence concerns the gene LGALS3BP and breast cancer.